Regeneron Pharmaceuticals, Inc. (REGN) Down 4.6% — Is It Time to Offload Shares?
Regeneron Pharmaceuticals, Inc. (REGN) is under heavy pressure on Monday, last trading at $752.04. That is a $36.00 decline from the prior close of $788.04. The selling has deepened as the session has worn on. An early-morning quote had the stock at $763.31, down 3.14%, before sellers pushed it lower. REGN now trades roughly 12.5% below its 52-week high of $859.34, a level it reached on September 3, 2026. The stock has given back a meaningful share of its gains in less than a month.
Volume stands at approximately 499,222 shares so far, compared with a 90-day average of about 883,242. With the regular session still open, turnover is running at roughly 57% of a typical full day.
Why Regeneron Pharmaceuticals, Inc. Price is Moving Lower
The clearest weight on the stock is legal overhang tied to Regeneron's cancer-trial disclosures. On September 15, a report described federal securities class-action suits alleging that management understated the risks in the Phase III fianlimab-Libtayo program. These are allegations, not a court finding. Still, they strike at a program investors have treated as an important extension of the company's oncology franchise. Litigation of this kind rarely resolves quickly, and the uncertainty over both the trial's prospects and the company's disclosure record is proving hard for the market to price. The decline also stands out against a mostly steady Health Care group. Danaher Corporation (DHR) is up 1.28% and Gilead Sciences, Inc. (GILD) is up 0.78%, while Merck & Co., Inc. (MRK) has slipped just 0.15%. That contrast points to company-specific concern rather than a sector-wide retreat.
Today's weakness does not stem from a deterioration in reported results. Regeneron's most recent quarter, reported on July 30, was strong on the headline numbers. Non-GAAP EPS came in at $14.29 against a $10.58 consensus, and revenue reached $4.29 billion versus the $3.80 billion expected. Year over year, adjusted EPS rose 11% and revenue climbed 17%. The quarter did carry a softer detail beneath the beat. GAAP net income fell 7% to $1.297 billion from $1.392 billion, a reminder that bottom-line progress has not kept pace with the top line.
Wall Street support has not wavered publicly. On September 27, J.P. Morgan maintained its Buy rating and $900 price target, which implies considerable upside from the current quote. On the pipeline front, the company's obesity candidate REGN20934 entered a Phase 1 safety study on September 26, 2026. That gives Regeneron a foothold in one of the industry's most closely watched categories. At this early stage, however, it is a safety study rather than proof of efficacy, and it offers little near-term offset to the legal and pipeline-risk concerns now driving the stock.
What is the Regeneron Pharmaceuticals, Inc. Rating - Should I Sell?
Weiss Ratings assigns REGN a C rating. Current recommendation is Hold. The rating reflects a company with sound fundamentals whose stock has delivered an uneven experience for shareholders. Today's decline is a fresh example of that gap.
The operating side of the ledger is where Regeneron holds up best. The Excellent rating on the Efficiency Index is supported by a 27.86% profit margin. That is a strong level of profitability for a company still funding a broad, research-heavy pipeline spanning ophthalmology, immunology, oncology and now obesity. A 14.04% ROE is solid rather than spectacular, but it comes alongside a balance sheet that is rated Excellent on the Solvency Index. That financial footing matters now: it gives the company room to fund late-stage programs and absorb litigation costs without straining its finances. The Growth Index is rated Good, and it rests on revenue growth of 16.73%. The rating stops short of Excellent largely because the 7% drop in second-quarter GAAP net income shows earnings momentum lagging sales momentum.
Where the picture turns less favorable is in how the stock itself has traded. Regeneron is rated Weak on both the Total Return Index and the Volatility Index, and the recent price path explains both. The stock set its 52-week high of $859.34 on September 3 and now sits about 12.5% below it after today's slide. A drawdown of that size in a matter of weeks, capped by a 4.57% single-session drop, shows why the Volatility Index is not rated higher. It also shows why returns have not rewarded holders over the measurement period. The valuation, at 19.48 times forward earnings against trailing EPS of $40.46, is not stretched. But a reasonable multiple has not protected the shares from headline risk.
Within the Health Care sector, Regeneron is in line with Merck & Co., Inc. (MRK, C), Gilead Sciences, Inc. (GILD, C) and Pfizer Inc. (PFE, C). It trails Thermo Fisher Scientific Inc. (TMO, C+), which carries a modestly better risk/reward profile in Weiss's framework. The clustering of large-cap Health Care names at C and C+ reflects a group where solid fundamentals are being offset by uneven stock performance.
About Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc. (REGN) is a Health Care company that discovers, develops and commercializes medicines for serious diseases. The company is headquartered in Tarrytown, New York. It built its reputation on proprietary antibody-discovery technology, most notably its VelocImmune platform, which has produced a string of approved therapies. Its ophthalmology franchise centers on EYLEA and the higher-dose EYLEA HD, used to treat wet age-related macular degeneration, diabetic macular edema and related retinal conditions.
Immunology has become a central growth engine through Dupixent, developed and commercialized with Sanofi. Dupixent has expanded across atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis and COPD, among other indications. In oncology, Regeneron markets Libtayo, a PD-1 inhibitor. It is working to extend that franchise through combination approaches such as the fianlimab-Libtayo program and through bispecific antibodies including linvoseltamab and odronextamab. The broader portfolio also includes Praluent for cholesterol management, Kevzara for rheumatoid arthritis and Evkeeza for a rare genetic lipid disorder.
Regeneron's competitive advantages lie in its in-house discovery engine, its large-scale human genetics research through the Regeneron Genetics Center, and its record of turning internally discovered antibodies into multi-indication medicines. The company is also pushing into newer therapeutic areas, including obesity with its REGN20934 candidate. These assets give Regeneron a deep and diversified pipeline. They do not shield it from the risks inherent to drug development, including clinical setbacks, biosimilar competition to established products and regulatory uncertainty.
Investor Outlook
Regeneron Pharmaceuticals, Inc. (REGN) carries a Weiss Rating of C (Hold). Strong recent results and a healthy balance sheet are currently being outweighed by legal uncertainty around the fianlimab-Libtayo disclosures. Investors should watch how the securities class actions develop, whether upcoming data from the fianlimab-Libtayo program eases concerns about its risk profile, and whether the next quarterly report can show GAAP earnings keeping pace with double-digit revenue growth. See full rankings of all C-rated Health Care stocks inside the Weiss Stock Screener.
--